文献速递MDS 与骨髓增殖性肿瘤

MPN抗炎治疗:靶向TNFR1与TNFR2在JAK2-V617F疾病中的作用

Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F-induced disease.
PubMed 文献 · Blood Adv · 2021-01-01

该研究在JAK2+/VF敲入小鼠模型中探讨抗TNFR1和抗TNFR2抗体对MPN样疾病的治疗作用。抗TNFR2抗体降低白细胞并调节多种血清细胞因子,但未改善红细胞压积和脾大;抗TNFR1抗体轻度抑制升高的红细胞压积(-10.7%)并减轻脾大(脾重减少22%)。研究表明TNFR1和TNFR2在JAK2-V617F诱导疾病中作用不同,可能对今后治疗策略有参考价值。

要点

  • 抗TNFR2抗体降低白细胞并调节CXCL2、CXCL5、IL-12(p40)及M-CSF等血清因子。
  • 抗TNFR1抗体轻度降低升高的红细胞压积(-10.7%)并减轻脾大(脾重减少22%)。
  • TNFR1与TNFR2在JAK2-V617F疾病中作用不同,可能为未来治疗提供靶点参考。

核心结论

  • TNFR1和TNFR2在JAK2-V617F诱导的MPN样疾病中发挥不同作用,可能对未来治疗策略有参考价值。

研究设计与样本

  • 使用JAK2+/VF敲入小鼠模型研究抗TNFR1和抗TNFR2抗体对MPN样疾病的治疗作用。
  • 检测指标包括外周血细胞计数、骨髓/脾组织病理学及血清炎症细胞因子水平。

主要发现

  • 抗TNFR2抗体治疗降低白细胞,并调节血清CXCL2、CXCL5、IL-12(p40)及M-CSF水平,但未改善红细胞压积和脾大。
  • 抗TNFR1抗体治疗轻度抑制升高的红细胞压积(-10.7%),并减轻脾大(脾重减少22%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic nonresolving inflammatory syndrome is a major disease feature in myeloproliferative neoplasms (MPNs). Systemic inflammation promotes the growth of the JAK2-V617F+ hematopoietic stem cell clone and is associated with constitutive symptoms (eg, fever, cachexia, and fatigue). Therefore, it is being discussed whether anti-inflammatory therapy, in addition to the well-established JAK inhibitor therapy, may be beneficial in the control of constitutive symptoms. Moreover, effective control of the inflammatory microenvironment may contribute to prevent transformation into secondary myelofibrosis and acute leukemia. Given the pivotal role of tumor necrosis factor α (TNF-α) in MPN and the distinct roles of TNF-α receptor 1 (TNFR1) and TNFR2 in inflammation, we investigated the therapeutic effects of αTNFR1 and αTNFR2 antibody treatment in MPN-like disease using the JAK2+/VF knock-in mouse model. Peripheral blood counts, bone marrow/spleen histopathology, and inflammatory cytokine levels in serum were investigated. αTNFR2 antibody treatment decreased white blood cells and modulated the serum levels of several cytokines [CXCL2, CXCL5, interleukin-12(p40)], as well as of macrophage colony-stimulating factor, but they lacked efficacy to ameliorate hematocrit and splenomegaly. αTNFR1 antibody treatment resulted in the mild suppression of elevated hematocrit of -10.7% and attenuated splenomegaly (22% reduction in spleen weight). In conclusion, our studies show that TNFR1 and TNFR2 play different roles in the biology of JAK2-V617F-induced disease that may be of relevance in future therapeutic settings.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Müller P, Baldauf CK, Haage TR, et al. Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F-induced disease. Blood Adv. 2021. PMID: 34592754. doi:10.1182/bloodadvances.2021004438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。